Xilio Therapeutics Extends Cash Runway Into 2027

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn announcement from Xilio Therapeutics ( (XLO) ) is now available. In June 2025, Xilio Therapeutics issued 66,676,000 Series B warrants and 66,676,000 Series C warrants as part of a follow-on public offering. By December 31, 2025, 48,207,815 Series B warrants had been exercised, resulting in the issuance of 8,202,815 shares of common stock and 40,005,000 prefunded warrants, and generating $35.8 million in gross proceeds before transaction costs. As a result of the warrant activity and prior prefunded warrant exercises, Xilio had 67,540,930 shares of common stock outstanding as of January 2, 2026, while 48,207,815 Series C warrants remained outstanding and 18,468,185 Series C warrants expired in line with the lapse of unexercised Series B warrants. The company indicated that, based on its current operating plans and the net proceeds from the Series B warrant exercises, its cash and cash equivalents are expected to fund operating expenses and capital expenditures into the second quarter of 2027, strengthening its near- to medium-term financial runway and providing additional visibility for investors and other stakeholders. The most recent analyst rating on (XLO) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page. Spark’s Take on XLO Stock According to Spark, TipRanks’ AI Analyst, XLO is a Neutral. The score is held down primarily by weak financial quality (large losses, ongoing negative cash flow, and negative equity), with technical indicators also bearish (below key moving averages and negative MACD). Strong revenue growth and improving cash burn provide some offset, but valuation signals are limited due to negative earnings and no dividend data. To see Spark’s full report on XLO stock, click here. More about Xilio Therapeutics Xilio Therapeutics, Inc. is a biotechnology company that accesses capital through public equity markets, including the issuance of common stock and warrants, to fund its operations and development activities in the life sciences sector. Average Trading Volume: 626,066 Technical Sentiment Signal: Sell Current Market Cap: $35.26M